Advances in liposomal drug delivery to cancer: An overview

Saraf, Shivani; Jain, Ankit; Tiwari, Ankita; Verma, Arunima; Panda, Pritish Kumar; Jain, Sanjay

doi:10.1016/j.jddst.2020.101549

Cited by 126 publications

(75 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these nanocarriers, liposomes and niosomes have great potential in multiple drug delivery. Niosomes are formed of bilayer spherical vesicles, which consist of nonionic surfactants and cholesterol in an aqueous medium [15], while liposomes are bilayer vesicles made by phospholipids enclosing an aqueous medium [16]. Both have efficiency in encapsulating hydrophilic and hydrophobic drugs at the aqueous layer and the lipid bilayer, respectively.…”

Section: Introductionmentioning

confidence: 99%

Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation

et al. 2021

View full text Add to dashboard Cite

Gemcitabine (Gem) and cisplatin (Cis) are currently being used for lung cancer treatment, but they are highly toxic in high dosages. This research aimed to develop a niosome formulation containing a low-dosage Gem and Cis (NGC), as an alternative formulation for lung cancer treatment. NGC was prepared using a very simple heating method and was further optimized by D-optimal mixture design. The optimum NGC formulation with particle size, polydispersity index (PDI), and zeta potential of 166.45 nm, 0.16, and −15.28 mV, respectively, was obtained and remained stable at 27 °C with no phase separation for up to 90 days. The aerosol output was 96.22%, which indicates its suitability as aerosolized formulation. An in vitro drug release study using the dialysis bag diffusion technique showed controlled release for both drugs up to 24 h penetration. A cytotoxicity study against normal lung (MRC5) and lung cancer (A549) cell lines was investigated. The results showed that the optimized NGC had reduced cytotoxicity effects against both MRC5 and A549 when compared with the control (Gem + Cis alone) from very toxic (IC50 < 1.56 µg/mL) to weakly toxic (IC50 280.00 µg/mL) and moderately toxic (IC50 = 46.00 µg/mL), respectively, after 72 h of treatment. These findings revealed that the optimized NGC has excellent potential and is a promising prospect in aerosolized delivery systems to treat lung cancer that warrants further investigation.

show abstract

Section: Introductionmentioning

confidence: 99%

Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The release rate of DOX was high at 42°C compared with 37°C and enabled higher tumor growth suppression in vivo if compared with the free drug-treated group. Growth factor receptor-bound protein-2 liposomes were prepared to inhibit the production of the growth factor receptor-bound protein-2 and, thereby, to reduce the proliferation of tumor cells ( Saraf et al, 2020 ). TSL administration can be done directly in suspension (e.g., intravenous injection) or by loading them into injectable hydrogels to sequential delivery of multiple drugs ( Lu and Ten Hagen, 2020 ; Palmese et al, 2020 ).…”

Section: Strategies For Porous Scaffold Bioactivation By Drug Entrapment and Deliverymentioning

confidence: 99%

Review on Computer-Aided Design and Manufacturing of Drug Delivery Scaffolds for Cell Guidance and Tissue Regeneration

Salerno¹,

Netti

2021

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

In the last decade, additive manufacturing (AM) processes have updated the fields of biomaterials science and drug delivery as they promise to realize bioengineered multifunctional devices and implantable tissue engineering (TE) scaffolds virtually designed by using computer-aided design (CAD) models. However, the current technological gap between virtual scaffold design and practical AM processes makes it still challenging to realize scaffolds capable of encoding all structural and cell regulatory functions of the native extracellular matrix (ECM) of health and diseased tissues. Indeed, engineering porous scaffolds capable of sequestering and presenting even a complex array of biochemical and biophysical signals in a time- and space-regulated manner, require advanced automated platforms suitable of processing simultaneously biomaterials, cells, and biomolecules at nanometric-size scale. The aim of this work was to review the recent scientific literature about AM fabrication of drug delivery scaffolds for TE. This review focused on bioactive molecule loading into three-dimensional (3D) porous scaffolds, and their release effects on cell fate and tissue growth. We reviewed CAD-based strategies, such as bioprinting, to achieve passive and stimuli-responsive drug delivery scaffolds for TE and cancer precision medicine. Finally, we describe the authors’ perspective regarding the next generation of CAD techniques and the advantages of AM, microfluidic, and soft lithography integration for enhancing 3D porous scaffold bioactivation toward functional bioengineered tissues and organs.

show abstract

“…PEG is a hydrophilic, biocompatible, and biologically inert polymer, which is used to enhance the stability of NPs [173]. Moreover, the coating allows loading of specific ligands, antibodies, peptides, drugs, folic acid, aptamers, tumor markers, transferrin, vitamins, etc., on the surface of particles offering an exciting tool to make NPs target-specific and increase their therapeutic benefit [174][175][176]. These ligands can be easily conjugated onto PEG´s distal end via various chemical coupling strategies [177].…”

Section: Liposomesmentioning

confidence: 99%

Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives

Buociková

Ríos-Mondragón

Pilalis

et al. 2020

Cancers

View full text Add to dashboard Cite

Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solubility, and minimizing off-target effects. Furthermore, the omics technologies, as powerful molecular epidemiology screening tools, enable new diagnostic and prognostic epigenetic biomarker identification, allowing for patient stratification and tailored management. In combination with new-generation epi-drugs, nanomedicine can help to overcome low therapeutic efficacy in treatment-resistant tumors. This review provides an overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment and summarizes the latest nano-based targeted delivery approaches for epi-drugs. Moreover, it highlights the current limitations and obstacles associated with applying these experimental strategies in the clinics.

show abstract

Advances in liposomal drug delivery to cancer: An overview

Cited by 126 publications

References 112 publications

Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation

Aerosolized Niosome Formulation Containing Gemcitabine and Cisplatin for Lung Cancer Treatment: Optimization, Characterization and In Vitro Evaluation

Review on Computer-Aided Design and Manufacturing of Drug Delivery Scaffolds for Cell Guidance and Tissue Regeneration

Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives

Contact Info

Product

Resources

About